Publications by authors named "Bensinger D"

Background: The potentiator ivacaftor (VX-770) has been approved for therapy of 38 cystic fibrosis (CF) mutations (∼10% of the patient population) associated with a gating defect of the CF transmembrane conductance regulator (CFTR). Despite the success of VX-770 treatment of patients carrying at least one allele of the most common gating mutation G551D-CFTR, some lung function decline and P. aeruginosa colonization persist.

View Article and Find Full Text PDF
Article Synopsis
  • The ubiquitin-proteasome system (UPS) is a key target for drugs that treat certain blood cancers, with current drug discovery focusing on compounds that bind to it permanently or semi-permanently.
  • The study reports on enhancing the effectiveness of a class of compounds known as α-ketoamides, aiming to improve their cytotoxicity and target specificity for treating leukemia.
  • The research indicates that modifying the α-ketoamide structure, particularly by adding a 3-phenoxy group, boosts its ability to inhibit the proteasome and shows promise for safer therapeutic options compared to existing treatments like bortezomib.
View Article and Find Full Text PDF

The use of covalent irreversible binding inhibitors is an established concept for drug development. Usually, the discovery of new irreversible kinase inhibitors occurs serendipitously, showing that efficient rational approaches for the rapid discovery of new drugs are needed. Herein, we report a virtual screening strategy that led to the discovery of irreversible inhibitors of FMS-like tyrosine kinase 3 (FLT3) involved in the pathogenesis of acute myeloid leukemia.

View Article and Find Full Text PDF

The ubiquitin/proteasome system is the major protein degradation pathway in eukaryotes with several key catalytic cores. Targeting the β5 subunit with small-molecule inhibitors is an established therapeutic strategy for hematologic cancers. Herein, we report a mouse-trap-like conformational change that influences molecular recognition depending on the substitution pattern of a bound ligand.

View Article and Find Full Text PDF

Activating mutations of FMS-like tyrosine kinase 3 (FLT3) are present in ∼30 % of patients with acute myeloid leukemia (AML) and are associated with poor prognosis. Point mutations in the tyrosine kinase domain (TKD) are observed as primary mutations or are acquired as secondary mutations in FLT3 with internal tandem duplications (ITDs) after treatment with tyrosine kinase inhibitors (TKIs). Although dozens of potent inhibitors against FLT3 ITD have been reported, activating TKD point mutations, especially at residues F691 and D835, remain the leading cause for therapy resistance, highlighting the consistent need for new potent inhibitors.

View Article and Find Full Text PDF

This paper examines the nature of visual representations that direct ongoing performance in sensorimotor tasks. Performance of such natural tasks requires relating visual information from different gaze positions. To explore this we used the technique of making task relevant display changes during saccadic eye movements.

View Article and Find Full Text PDF

We introduce a new technique for classifying many photoreceptors simultaneously in fresh, excised primate retina on the basis of their absorptance spectra. Primate retina is removed from the pigment epithelium and illuminated under a microscope from the same direction as in the intact eye. To facilitate the guiding of light into the receptor outer segments, the optical axes of the photoreceptors are oriented parallel to the optical axis of the microscope.

View Article and Find Full Text PDF